Description: Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
Home Page: boundlessbio.com
9880 Campus Point Drive
San Diego,
CA
92121
United States
Phone:
858 766 9912
Officers
Name | Title |
---|---|
Dr. Jonathan E. Lim M.D. | Co-Founder & Independent Chairman |
Mr. Zachary Hornby | CEO, President & Director |
Dr. Christian Hassig Ph.D. | Chief Scientific Officer |
Mr. David Hinkle | Senior VP of Finance & Controller |
Ms. Jessica Oien J.D. | Chief Legal Officer & Corporate Secretary |
Mr. Neil Abdollahian M.B.A., M.S. | Chief Business Officer |
Mr. Anthony Pinkerton Ph.D. | Senior Vice President of Drug Discovery |
Ms. Meredith Wesley | Senior Vice President of Talent & Culture |
Dr. Peter Krein Ph.D. | Senior Vice President of Precision Medicine |
Ms. Amy Berkley Ph.D. | Senior Vice President of Program Team |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 0.4457 |
Price-to-Sales TTM: | 0 |
IPO Date: | 2024-03-28 |
Fiscal Year End: | December |
Full Time Employees: | 72 |